Roselinde Kaiser
Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Depressive Disorder, Major | 10 | 2022 | 304 | 2.950 |
Why?
| Reward | 7 | 2023 | 208 | 1.820 |
Why?
| Frontal Lobe | 3 | 2019 | 139 | 1.690 |
Why?
| Cerebral Cortex | 4 | 2019 | 386 | 1.680 |
Why?
| Mood Disorders | 2 | 2023 | 117 | 1.680 |
Why?
| Depression | 6 | 2023 | 1147 | 1.620 |
Why?
| Bipolar Disorder | 2 | 2023 | 208 | 1.420 |
Why?
| Affect | 4 | 2023 | 244 | 1.330 |
Why?
| Neural Pathways | 8 | 2022 | 260 | 1.290 |
Why?
| Rest | 3 | 2019 | 100 | 1.140 |
Why?
| Anhedonia | 2 | 2023 | 9 | 1.060 |
Why?
| Sertraline | 2 | 2022 | 26 | 0.990 |
Why?
| Connectome | 3 | 2021 | 63 | 0.970 |
Why?
| Anticipation, Psychological | 1 | 2023 | 17 | 0.860 |
Why?
| Depressive Disorder | 2 | 2017 | 336 | 0.830 |
Why?
| Dopamine | 3 | 2019 | 237 | 0.790 |
Why?
| Magnetic Resonance Imaging | 16 | 2022 | 3122 | 0.780 |
Why?
| Nucleus Accumbens | 1 | 2023 | 123 | 0.770 |
Why?
| Amygdala | 1 | 2023 | 179 | 0.770 |
Why?
| Prefrontal Cortex | 3 | 2018 | 267 | 0.750 |
Why?
| Individuality | 2 | 2018 | 146 | 0.690 |
Why?
| Nerve Net | 2 | 2019 | 228 | 0.690 |
Why?
| Rumination, Cognitive | 1 | 2019 | 6 | 0.660 |
Why?
| Parietal Lobe | 2 | 2018 | 41 | 0.660 |
Why?
| Ventral Striatum | 1 | 2018 | 8 | 0.640 |
Why?
| Dopamine Plasma Membrane Transport Proteins | 1 | 2018 | 40 | 0.630 |
Why?
| Emotions | 3 | 2021 | 477 | 0.610 |
Why?
| Brain | 9 | 2022 | 2373 | 0.610 |
Why?
| Young Adult | 12 | 2023 | 10518 | 0.570 |
Why?
| Facial Recognition | 1 | 2015 | 25 | 0.510 |
Why?
| Nonlinear Dynamics | 1 | 2015 | 88 | 0.490 |
Why?
| Stress, Psychological | 1 | 2023 | 975 | 0.490 |
Why?
| Adolescent | 9 | 2023 | 17922 | 0.420 |
Why?
| Attention | 1 | 2014 | 394 | 0.380 |
Why?
| Adult | 15 | 2023 | 30789 | 0.370 |
Why?
| Executive Function | 3 | 2023 | 373 | 0.360 |
Why?
| Memory, Short-Term | 2 | 2023 | 224 | 0.330 |
Why?
| Humans | 28 | 2023 | 115741 | 0.320 |
Why?
| Functional Neuroimaging | 2 | 2019 | 67 | 0.280 |
Why?
| Neuropsychological Tests | 2 | 2023 | 920 | 0.270 |
Why?
| Brain Mapping | 5 | 2022 | 522 | 0.260 |
Why?
| Female | 17 | 2023 | 60018 | 0.260 |
Why?
| Male | 15 | 2023 | 56050 | 0.260 |
Why?
| Stroop Test | 4 | 2022 | 26 | 0.260 |
Why?
| Psychiatric Status Rating Scales | 2 | 2015 | 485 | 0.210 |
Why?
| Cues | 2 | 2020 | 298 | 0.180 |
Why?
| Impulsive Behavior | 1 | 2021 | 109 | 0.180 |
Why?
| Biomarkers | 2 | 2022 | 3471 | 0.180 |
Why?
| Antidepressive Agents | 1 | 2022 | 195 | 0.180 |
Why?
| Craving | 1 | 2020 | 31 | 0.180 |
Why?
| Reaction Time | 3 | 2022 | 374 | 0.180 |
Why?
| Sex Offenses | 1 | 2022 | 148 | 0.170 |
Why?
| Learning | 1 | 2023 | 358 | 0.170 |
Why?
| Antidepressive Agents, Second-Generation | 1 | 2019 | 38 | 0.170 |
Why?
| Nicotine | 1 | 2021 | 266 | 0.160 |
Why?
| Conditioning, Operant | 1 | 2018 | 99 | 0.150 |
Why?
| Psychological Trauma | 1 | 2018 | 55 | 0.150 |
Why?
| Adult Survivors of Child Abuse | 1 | 2017 | 20 | 0.140 |
Why?
| Smoking Cessation | 1 | 2021 | 377 | 0.140 |
Why?
| Positron-Emission Tomography | 1 | 2018 | 284 | 0.140 |
Why?
| Sulpiride | 1 | 2016 | 5 | 0.140 |
Why?
| Dopamine Antagonists | 1 | 2016 | 22 | 0.140 |
Why?
| Sex Characteristics | 1 | 2021 | 641 | 0.140 |
Why?
| Dopaminergic Neurons | 1 | 2016 | 43 | 0.130 |
Why?
| Machine Learning | 1 | 2019 | 321 | 0.130 |
Why?
| Alcoholism | 1 | 2022 | 717 | 0.130 |
Why?
| Corpus Striatum | 1 | 2016 | 124 | 0.130 |
Why?
| Synaptic Transmission | 1 | 2016 | 232 | 0.120 |
Why?
| Mental Disorders | 1 | 2021 | 902 | 0.110 |
Why?
| Stress Disorders, Post-Traumatic | 2 | 2018 | 759 | 0.110 |
Why?
| Photic Stimulation | 1 | 2014 | 203 | 0.110 |
Why?
| Cognition Disorders | 1 | 2017 | 475 | 0.110 |
Why?
| Choice Behavior | 1 | 2013 | 159 | 0.100 |
Why?
| Psychomotor Performance | 1 | 2014 | 278 | 0.100 |
Why?
| Image Processing, Computer-Assisted | 1 | 2015 | 699 | 0.100 |
Why?
| Severity of Illness Index | 1 | 2019 | 2586 | 0.100 |
Why?
| Oxygen | 1 | 2015 | 837 | 0.090 |
Why?
| Decision Making | 1 | 2017 | 791 | 0.090 |
Why?
| Case-Control Studies | 1 | 2015 | 3037 | 0.080 |
Why?
| Anxiety | 1 | 2013 | 854 | 0.070 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1361 | 0.060 |
Why?
| Double-Blind Method | 2 | 2019 | 1660 | 0.060 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 963 | 0.060 |
Why?
| Gyrus Cinguli | 1 | 2022 | 69 | 0.050 |
Why?
| Middle Aged | 3 | 2018 | 27069 | 0.050 |
Why?
| Bupropion | 1 | 2020 | 39 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2021 | 435 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2012 | 2207 | 0.040 |
Why?
| Psychometrics | 1 | 2021 | 615 | 0.040 |
Why?
| Avoidance Learning | 1 | 2016 | 62 | 0.030 |
Why?
| Cognition | 1 | 2021 | 981 | 0.030 |
Why?
| Verbal Behavior | 1 | 2013 | 43 | 0.030 |
Why?
| Task Performance and Analysis | 1 | 2013 | 160 | 0.030 |
Why?
| Motivation | 1 | 2016 | 498 | 0.030 |
Why?
| Carboplatin | 1 | 2012 | 139 | 0.020 |
Why?
| Paclitaxel | 1 | 2012 | 192 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2012 | 724 | 0.020 |
Why?
| Indoles | 1 | 2012 | 309 | 0.020 |
Why?
| Students | 1 | 2013 | 503 | 0.020 |
Why?
| Prospective Studies | 1 | 2020 | 6276 | 0.020 |
Why?
| Neoplasm Staging | 1 | 2012 | 1178 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2012 | 1870 | 0.020 |
Why?
| Treatment Outcome | 1 | 2020 | 9162 | 0.020 |
Why?
| Child | 1 | 2022 | 18503 | 0.010 |
Why?
| Cohort Studies | 1 | 2012 | 4949 | 0.010 |
Why?
| Aged | 1 | 2012 | 19294 | 0.010 |
Why?
|
|
Kaiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|